Schizophrenia: A neurodevelopmental disorder - Integrative genomic hypothesis and therapeutic implications from a transgenic mouse model

Schizophrenia Research

Volumn 143, Issue 2-3, 2013, Pages 367-376

  Stachowiak, M K ^a   Kucinski, A ^a   Curl, R ^a   Syposs, C ^a   Yang, Y ^b   Narla, S ^a   Terranova, C ^a   Prokop, D ^a   Klejbor, I ^c   Bencherif, M ^d   Birkaya, B ^a   Corso, T ^e   Parikh, A ^b   Tzanakakis, E S ^b   Wersinger, S ^a,b   Stachowiak, E K ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d TARGACEPT INC   (United States)

^e LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

7 nicotinic receptors; Atypical neuroleptics; Fibroblast growth factor receptor 1; Midbrain dopamine neurons; Nicotinic acetylcholine receptors; Transgenic mouse model of schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FLUPENTIXOL; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NICOTINIC AGENT; NICOTINIC RECEPTOR; QUETIAPINE; SEROTONIN 1 ANTAGONIST; SEROTONIN 2A ANTAGONIST; TC 5619; TC 7020; UNCLASSIFIED DRUG; VOLINANSERIN;

ANIMAL BEHAVIOR; BRAIN NERVE CELL; CELL STRUCTURE; CLINICAL FEATURE; COGNITIVE DEFECT; CONNECTOME; DEVELOPMENTAL DISORDER; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; EMBRYONIC STEM CELL; ENZYME INHIBITION; EXPERIMENTAL MODEL; FGF2 GENE; FGFR1 GENE; GENE; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE INTERACTION; GENE MUTATION; GENETIC ANALYSIS; GESTATION PERIOD; ILLNESS TRAJECTORY; INTRACELLULAR SIGNALING; MITOSIS; NERVE CELL DIFFERENTIATION; NERVE CELL NETWORK; NEURAL STEM CELL; NEUROBLAST; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NONHUMAN; NUCLEAR FGFR1 SIGNALLING; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TARGETING; PSYCHOSOCIAL DISORDER; PSYCHOSOCIAL WITHDRAWAL; RECEPTOR BLOCKING; REVIEW; SCHIZOPHRENIA; SENSORY GATING; SOCIAL INTERACTION; TRANSGENIC MOUSE; TREATMENT RESPONSE; WORKING MEMORY;

ANIMALS; DISEASE MODELS, ANIMAL; GENOMICS; HUMANS; MICE; SCHIZOPHRENIA;

EID: 84872416150     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.11.004     Document Type: Review

References (130)

1. Abel K.M., O'Keane V., Murray R.M. Enhancement of the prolactin response to d-fenfluramine in drug-naive schizophrenic patients. Br. J. Psychiatry 1996, 168:57-60.
2. Acker B.A., Jacobsen E.J., Rogers B.N., Wishka D.G., Reitz S.C., Piotrowski D.W., Myers J.K., Wolfe M.L., Groppi V.E., Thornburgh B.A., Tinholt P.M., Walters R.R., Olson B.A., Fitzgerald L., Staton B.A., Raub T.J., Krause M., Li K.S., Hoffmann W.E., Hajos M., Hurst R.S., Walker D.P. Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity. Bioorg. Med. Chem. Lett. 2008, 18:3611-3615.
3. Adan A., Prat G., Sanchez-Turet M. Effects of nicotine dependence on diurnal variations of subjective activation and mood. Addiction 2004, 99:1599-1607.
4. Albuisson J., Pecheux C., Carel J.C., Lacombe D., Leheup B., Lapuzina P., Bouchard P., Legius E., Matthijs G., Wasniewska M., Delpech M., Young J., Hardelin J.P., Dode C. Kallmann syndrome: 14 novel mutations in KAL1 and FGFR1 (KAL2). Hum. Mutat. 2005, 25:98-99.
5. Attard A., Taylor D.M. Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?. CNS Drugs 2012, 26:491-508.
6. Ayalew M., Le-Niculescu H., Levey D.F., Jain N., Changala B., Patel S.D., Winiger E., Breier A., Shekhar A., Amdur R., Koller D., Nurnberger J.I., Corvin A., Geyer M., Tsuang M.T., Salomon D., Schork N.J., Fanous A.H., O'Donovan M.C., Niculescu A.B. Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol. Psychiatry 2012, 17:887-905.
7. Aznar S., Kostova V., Christiansen S.H., Knudsen G.M. Alpha 7 nicotinic receptor subunit is present on serotonin neurons projecting to hippocampus and septum. Synapse 2005, 55:196-200.
8. Baron O., Foerthmann B., Lee Y.W., Terranova C., Ratzka A., Stachowiak E.K., Grothe C., Claus P., Stachowiak M.K. Cooperation of nuclear FGFR1 and Nurr1 offers a new interactive mechanism in postmitotic development of mesencephalic dopaminergic neurons. J. Biol. Chem. 2012, 287:19827-19840.
9. Bartfai A., Levander S.E., Sedvall G. Smooth pursuit eye movements, clinical symptoms, CSF metabolites, and skin conductance habituation in schizophrenic patients. Biol. Psychiatry 1983, 18:971-987.
10. Bogerts B., Hantsch J., Herzer M. A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients, and schizophrenics. Biol. Psychiatry 1983, 18:951-969.
11. Braff D.L., Swerdlow N.R., Geyer M.A. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am. J. Psychiatry 1999, 156:596-602.
12. Braff D.L., Geyer M.A., Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl.) 2001, 156:234-258.
13. Bruno J.P., Jackson D., Zigmond M.J., Stricker E.M. Effect of dopamine-depleting brain lesions in rat pups: role of striatal serotonergic neurons in behavior. Behav. Neurosci. 1987, 101:806-811.
14. Buervenich S., Carmine A., Arvidsson M., Xiang F., Zhang Z., Sydow O., Jonsson E.G., Sedvall G.C., Leonard S., Ross R.G., Freedman R., Chowdari K.V., Nimgaonkar V.L., Perlmann T., Anvret M., Olson L. NURR1 mutations in cases of schizophrenia and manic-depressive disorder. Am. J. Med. Genet. 2000, 96:808-813.
15. Carlezon W.A., Duman R.S., Nestler E.J. The many faces of CREB. Trends Neurosci. 2005, 28:436-445.
16. Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 2006, 39(Suppl. 1):S10-S14.
17. Cools R. Dopaminergic control of the striatum for high-level cognition. Curr. Opin. Neurobiol. 2011, 21:402-407.
18. Cowen M.A., Green M. The Kallmann's syndrome variant (KSV) model of the schizophrenias. Schizophr. Res. 1993, 9:1-10.
19. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 1991, 148:1474-1486.
20. DeVito L.M., Konigsberg R., Lykken C., Sauvage M., Young W.S., Eichenbaum H. Vasopressin 1b receptor knock-out impairs memory for temporal order. J. Neurosci. 2009, 29:2676-2683.
21. Dome P., Lazary J., Kalapos M.P., Rihmer Z. Smoking, nicotine and neuropsychiatric disorders. Neurosci. Biobehav. Rev. 2010, 34:295-342.
22. Dono R. Fibroblast growth factors as regulators of central nervous system development and function. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 284:R867-R881.
23. Dunham-Ems S.M., Lee Y.W., Stachowiak E.K., Pudavar H., Claus P., Prasad P.N., Stachowiak M.K. Fibroblast growth factor receptor-1 (FGFR1) nuclear dynamics reveal a novel mechanism in transcription control. Mol. Biol. Cell 2009, 20:2401-2412.
24. Fang X., Stachowiak E.K., Dunham-Ems S.M., Klejbor I., Stachowiak M.K. Control of CREB-binding protein signaling by nuclear fibroblast growth factor receptor-1: a novel mechanism of gene regulation. J. Biol. Chem. 2005, 280:28451-28462.
25. Fatemi S.H., Folsom T.D. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr. Bull. 2009, 35:528-548.
26. Feng J., Chen J., Yan J., Jones I.R., Craddock N., Cook E.H., Goldman D., Heston L.L., Sommer S.S. Structural variants in the retinoid receptor genes in patients with schizophrenia and other psychiatric diseases. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 133B:50-53.
27. Fibiger H.C., Miller J.J. An anatomical and electrophysiological investigation of the serotonergic projection from the dorsal raphenucleus to the substantia nigra in the rat. Neuroscience 1977, 2:975-987.
28. Flajolet M., Wang Z., Futter M., Shen W., Nuangchamnong N., Bendor J., Wallach I., Nairn A.C., Surmeier D.J., Greengard P. FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity. Nat. Neurosci. 2008, 11:1402-1409.
29. Floresco S.B., Magyar O. Mesocortical dopamine modulation of executive functions: beyond working memory. Psychopharmacology (Berl.) 2006, 188:567-585.
30. Freedman R., Adams C.E., Leonard S. The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. J. Chem. Neuroanat. 2000, 20:299-306.
31. Fucile S., Palma E., Eusebi F., Miledi R. Serotonin antagonizes the human neuronal alpha7 nicotinic acetylcholine receptor and becomes an agonist after L248T alpha7 mutation. Neuroscience 2002, 110:169-179.
32. Fujimaki K., Takahashi T., Morinobu S. Association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia. PLoS One 2012, 7:e37087.
33. Fumagalli F., Bedogni F., Slotkin T.A., Racagni G., Riva M.A. Prenatal stress elicits regionally selective changes in basal FGF-2 gene expression in adulthood and alters the adult response to acute or chronic stress. Neurobiol. Dis. 2005, 20:731-737.
34. Ganat Y., Soni S., Chacon M., Schwartz M.L., Vaccarino F.M. Chronic hypoxia up-regulates fibroblast growth factor ligands in the perinatal brain and induces fibroblast growth factor-responsive radial glial cells in the sub-ependymal zone. Neuroscience 2002, 112:977-991.
35. Gaughran F., Payne J., Sedgwick P.M., Cotter D., Berry M. Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder. Brain Res. Bull. 2006, 70:221-227.
36. George T.P., Termine A., Sacco K.A., Allen T.M., Reutenauer E., Vessicchio J.C., Duncan E.J. A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: involvement of nicotinic receptor mechanisms. Schizophr. Res. 2006, 87:307-315.
37. Geyer M.A., McIlwain K.L., Paylor R. Mouse genetic models for prepulse inhibition: an early review. Mol. Psychiatry 2002, 7:1039-1053.
38. Goldman-Rakic P.S., Castner S.A., Svensson T.H., Siever L.J., Williams G.V. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl.) 2004, 174:3-16.
39. Grothe C., Timmer M. The physiological and pharmacological role of basic fibroblast growth factor in the dopaminergic nigrostriatal system. Brain Res. Rev. 2007, 54:80-91.
40. Guan Z.Z., Zhang X., Blennow K., Nordberg A. Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport 1999, 10:1779-1782.
41. Hajos M., Hurst R.S., Hoffmann W.E., Krause M., Wall T.M., Higdon N.R., Groppi V.E. The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J. Pharmacol. Exp. Ther. 2005, 312:1213-1222.
42. Hansson L.O., Waters N., Winblad B., Gottfries C.G., Carlsson A. Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortal brain tissue. J. Neural Transm. Gen. Sect. 1994, 98:217-235.
43. Harris J.G., Kongs S., Allensworth D., Martin L., Tregellas J., Sullivan B., Zerbe G., Freedman R. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 2004, 29:1378-1385.
44. Harrison P.J. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999, 122(Pt 4):593-624.
45. Hashimoto K., Shimizu E., Komatsu N., Nakazato M., Okamura N., Watanabe H., Kumakiri C., Shinoda N., Okada S., Takei N., Iyo M. Increased levels of serum basic fibroblast growth factor in schizophrenia. Psychiatry Res. 2003, 120:211-218.
46. Hauser T.A., Kucinski A., Jordan K.G., Gatto G.J., Wersinger S.R., Hesse R.A., Stachowiak E.K., Stachowiak M.K., Papke R.L., Lippiello P.M., Bencherif M. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem. Pharmacol. 2009, 78:803-812.
47. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr. Bull. 2009, 35:549-562.
48. Ikemoto K., Nishi K., Kunii Y., Wada A., Yang Q., Takase I., Nishimura A., Niwa S. A study of monoamine neuronal systems of schizophrenic patients: using forensic autopsy brains. Leg. Med. (Tokyo) 2009, 11(Suppl. 1):S165-S167.
49. Jaaro-Peled H., Hayashi-Takagi A., Seshadri S., Kamiya A., Brandon N.J., Sawa A. Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1. Trends Neurosci. 2009, 32:485-495.
50. Jablensky A., Morar B., Wiltshire S., Carter K., Dragovic M., Badcock J.C., Chandler D., Peters K., Kalaydjieva L. Polymorphisms associated with normal memory variation also affect memory impairment in schizophrenia. Genes Brain Behav. 2011, 10:410-417.
51. Jukkola T., Lahti L., Naserke T., Wurst W., Partanen J. FGF regulated gene-expression and neuronal differentiation in the developing midbrain-hindbrain region. Dev. Biol. 2006, 297:141-157.
52. Jungerius B.J., Hoogendoorn M.L., Bakker S.C., Van't Slot R., Bardoel A.F., Ophoff R.A., Wijmenga C., Kahn R.S., Sinke R.J. An association screen of myelin-related genes implicates the chromosome 22q11 PIK4CA gene in schizophrenia. Mol. Psychiatry 2008, 13:1060-1068.
53. Kamnasaran D., Muir W.J., Ferguson-Smith M.A., Cox D.W. Disruption of the neuronal PAS3 gene in a family affected with schizophrenia. J. Med. Genet. 2003, 40:325-332.
54. Katsel P., Davis K.L., Gorman J.M., Haroutunian V. Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizophr. Res. 2005, 77:241-252.
55. Klejbor I., Myers J.M., Hausknecht K., Corso T.D., Gambino A.S., Morys J., Maher P.A., Hard R., Richards J., Stachowiak E.K., Stachowiak M.K. Fibroblast growth factor receptor signaling affects development and function of dopamine neurons - inhibition results in a schizophrenia-like syndrome in transgenic mice. J. Neurochem. 2006, 97:1243-1258.
56. Klejbor I., Kucinski A., Wersinger S.R., Corso T., Spodnik J.H., Dziewiatkowski J., Morys J., Hesse R.A., Rice K.C., Miletich R., Stachowiak E.K., Stachowiak M.K. Serotonergic hyperinnervation and effective serotonin blockade in an FGF receptor developmental model of psychosis. Schizophr. Res. 2009, 113:308-321.
57. Kohnomi S., Suemaru K., Goda M., Choshi T., Hibino S., Kawasaki H., Araki H. Ameliorating effects of tropisetron on dopaminergic disruption of prepulse inhibition via the alpha(7) nicotinic acetylcholine receptor in Wistar rats. Brain Res. 2010, 1353:152-158.
58. Kucinski A., Syposs C., Wersinger S., Bencherif M., Stachowiak M.K., Stachowiak E.K. alpha7 neuronal nicotinic receptor agonist (TC-7020) reverses increased striatal dopamine release during acoustic PPI testing in a transgenic mouse model of schizophrenia. Schizophr. Res. 2012, 136:82-87.
59. Kumari V., Soni W., Sharma T. Influence of cigarette smoking on prepulse inhibition of the acoustic startle response in schizophrenia. Hum. Psychopharmacol. 2001, 16:321-326.
60. Laruelle M., Abi-Dargham A., Gil R., Kegeles L., Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol. Psychiatry 1999, 46:56-72.
61. Lee Y.W., Terranova C., Birkaya B., Narla S., Kehoe D., Parikh A., Dong S., Ratzka A., Brinkmann H., Aletta J.M., Tzanakakis E.S., Stachowiak E.K., Claus P., Stachowiak M.K. A novel nuclear FGF Receptor-1 partnership with retinoid and Nur receptors during developmental gene programming of embryonic stem cells. J. Cell. Biochem. 2012, 113:2920-2936.
62. Leonard S., Gault J., Hopkins J., Logel J., Vianzon R., Short M., Drebing C., Berger R., Venn D., Sirota P., Zerbe G., Olincy A., Ross R.G., Adler L.E., Freedman R. Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch. Gen. Psychiatry 2002, 59:1085-1096.
63. Leonard S., Mexal S., Freedman R. Smoking, genetics and schizophrenia: evidence for self medication. J. Dual Diagn. 2007, 3:43-59.
64. Levin E.D., Rezvani A.H. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. Biochem. Pharmacol. 2007, 74:1182-1191.
65. Levin E.D., Wilson W., Rose J.E., McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 1996, 15:429-436.
66. Levin E.D., Petro A., Caldwell D.P. Nicotine and clozapine actions on pre-pulse inhibition deficits caused by N-methyl-d-aspartate (NMDA) glutamatergic receptor blockade. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:581-586.
67. Levin E.D., McClernon F.J., Rezvani A.H. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl.) 2006, 184:523-539.
68. Lieberman J.A., Mailman R.B., Duncan G., Sikich L., Chakos M., Nichols D.E., Kraus J.E. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol. Psychiatry 1998, 44:1099-1117.
69. Livingstone P.D., Srinivasan J., Kew J.N., Dawson L.A., Gotti C., Moretti M., Shoaib M., Wonnacott S. Alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur. J. Neurosci. 2009, 29:539-550.
70. Maher P.A. Nuclear translocation of fibroblast growth factor (FGF) receptors in response to FGF-2. J. Cell Biol. 1996, 134:529-536.
71. Marrero M.B., Lucas R., Salet C., Hauser T.A., Mazurov A., Lippiello P.M., Bencherif M. An alpha7 nicotinic acetylcholine receptor-selective agonist reduces weight gain and metabolic changes in a mouse model of diabetes. J. Pharmacol. Exp. Ther. 2010, 332:173-180.
72. Martin L.F., Leonard S., Hall M.H., Tregellas J.R., Freedman R., Olincy A. Sensory gating and alpha-7 nicotinic receptor gene allelic variants in schizoaffective disorder, bipolar type. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B:611-614.
73. Meyer-Lindenberg A., Tost H. Neural mechanisms of social risk for psychiatric disorders. Nat. Neurosci. 2012, 15:663-668.
74. Meyer-Lindenberg A., Miletich R.S., Kohn P.D., Esposito G., Carson R.E., Quarantelli M., Weinberger D.R., Berman K.F. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci. 2002, 5:267-271.
75. Moskvina V., Craddock N., Holmans P., Nikolov I., Pahwa J.S., Green E., Owen M.J., O'Donovan M.C. Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk. Mol. Psychiatry 2009, 14:252-260.
76. Mueller H.T., Haroutunian V., Davis K.L., Meador-Woodruff J.H. Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. Brain Res. Mol. Brain Res. 2004, 121:60-69.
77. Murray R.M., Lewis S.W. Is schizophrenia a neurodevelopmental disorder?. Br. Med. J. (Clin. Res. Ed) 1987, 295:681-682.
78. Myers J.M., Martins G.G., Ostrowski J., Stachowiak M.K. Nuclear trafficking of FGFR1: a role for the transmembrane domain. J. Cell. Biochem. 2003, 88:1273-1291.
79. Newhouse P., Singh A., Potter A. Nicotine and nicotinic receptor involvement in neuropsychiatric disorders. Curr. Top. Med. Chem. 2004, 4:267-282.
80. O'Donovan M.C., Norton N., Williams H., Peirce T., Moskvina V., Nikolov I., Hamshere M., Carroll L., Georgieva L., Dwyer S., Holmans P., Marchini J.L., Spencer C.C., Howie B., Leung H.T., Giegling I., Hartmann A.M., Moller H.J., Morris D.W., Shi Y., Feng G., Hoffmann P., Propping P., Vasilescu C., Maier W., Rietschel M., Zammit S., Schumacher J., Quinn E.M., Schulze T.G., Iwata N., Ikeda M., Darvasi A., Shifman S., He L., Duan J., Sanders A.R., Levinson D.F., Adolfsson R., Osby U., Terenius L., Jonsson E.G., Cichon S., Nothen M.M., Gill M., Corvin A.P., Rujescu D., Gejman P.V., Kirov G., Craddock N., Williams N.M., Owen M.J. Analysis of 10 independent samples provides evidence for association between schizophrenia and a SNP flanking fibroblast growth factor receptor 2. Mol. Psychiatry 2009, 14:30-36.
81. Popolo M., McCarthy D.M., Bhide P.G. Influence of dopamine on precursor cell proliferation and differentiation in the embryonic mouse telencephalon. Dev. Neurosci. 2004, 26:229-244.
82. Postma P., Gray J.A., Sharma T., Geyer M., Mehrotra R., Das M., Zachariah E., Hines M., Williams S.C., Kumari V. A behavioural and functional neuroimaging investigation into the effects of nicotine on sensorimotor gating in healthy subjects and persons with schizophrenia. Psychopharmacology (Berl.) 2006, 184:589-599.
83. Potkin S.G., Macciardi F., Guffanti G., Fallon J.H., Wang Q., Turner J.A., Lakatos A., Miles M.F., Lander A., Vawter M.P., Xie X. Identifying gene regulatory networks in schizophrenia. Neuroimage 2010, 53:839-847.
84. Powell S.B., Zhou X., Geyer M.A. Prepulse inhibition and genetic mouse models of schizophrenia. Behav. Brain Res. 2009, 204:282-294.
85. Poyurovsky M., Koren D., Gonopolsky I., Schneidman M., Fuchs C., Weizman A., Weizman R. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur. Neuropsychopharmacol. 2003, 13:123-128.
86. Ralph R.J., Paulus M.P., Fumagalli F., Caron M.G., Geyer M.A. Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. J. Neurosci. 2001, 21:305-313.
87. Rapoport J.L., Giedd J.N., Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Mol. Psychiatry 2012, 17:1228-1238.
88. Reuss B., von Bohlen und Halbach O. Fibroblast growth factors and their receptors in the central nervous system. Cell Tissue Res. 2003, 313:139-157.
89. Riva M.A., Molteni R., Bedogni F., Racagni G., Fumagalli F. Emerging role of the FGF system in psychiatric disorders. Trends Pharmacol. Sci. 2005, 26:228-231.
90. Rodriguez-Murillo L., Gogos J.A., Karayiorgou M. The genetic architecture of schizophrenia: new mutations and emerging paradigms. Annu. Rev. Med. 2012, 63:63-80.
91. Rodriguez-Pallares J., Guerra M.J., Labandeira-Garcia J.L. Elimination of serotonergic cells induces a marked increase in generation of dopaminergic neurons from mesencephalic precursors. Eur. J. Neurosci. 2003, 18:2166-2174.
92. Schmidt C.J., Kehne J.H., Carr A.A., Fadayel G.M., Humphreys T.M., Kettler H.J., McCloskey T.C., Padich R.A., Taylor V.L., Sorensen S.M. Contribution of serotonin neurotoxins to understanding psychiatric disorders: the role of 5-HT2 receptors in schizophrenia and antipsychotic activity. Int. Clin. Psychopharmacol. 1993, 8(Suppl. 2):25-32.
93. Schultz W. Getting formal with dopamine and reward. Neuron 2002, 36:241-263.
94. Shao L., Vawter M.P. Shared gene expression alterations in schizophrenia and bipolar disorder. Biol. Psychiatry 2008, 64:89-97.
95. Simpson E.H., Kellendonk C., Kandel E. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 2010, 65:585-596.
96. Stachowiak M.K. A novel nuclear FGF receptor-1 partnership with retinoid and Nur receptors in neuronal programming of embryonic stem cells 2012, (New York, NY).
97. Stachowiak M.K., Bruno J.P., Snyder A.M., Stricker E.M., Zigmond M.J. Apparent sprouting of striatal serotonergic terminals after dopamine-depleting brain lesions in neonatal rats. Brain Res. 1984, 291:164-167.
98. Stachowiak M.K., Maher P.A., Joy A., Mordechai E., Stachowiak E.K. Nuclear accumulation of fibroblast growth factor receptors is regulated by multiple signals in adrenal medullary cells. Mol. Biol. Cell 1996, 7:1299-1317.
99. Stachowiak M.K., Fang X., Myers J.M., Dunham S.M., Berezney R., Maher P.A., Stachowiak E.K. Integrative nuclear FGFR1 signaling (INFS) as a part of a universal "feed-forward-and-gate" signaling module that controls cell growth and differentiation. J. Cell. Biochem. 2003, 90:662-691.
100. Stachowiak M.K., Maher P.A., Stachowiak E.K. Integrative nuclear signaling in cell development - a role for FGF receptor-1. DNA Cell Biol. 2007, 26:811-826.
101. Stachowiak M.K., Maher P.A., Stachowiak E.K. Integrative nuclear signaling in cell development - a role for FGF receptor-1. DNA Cell Biol. 2007, 26:811-826.
102. Stachowiak E.K., Roy I., Lee Y.W., Capacchietti M., Aletta J.M., Prasad P.N., Stachowiak M.K. Targeting novel integrative nuclear FGFR1 signaling by nanoparticle-mediated gene transfer stimulates neurogenesis in the adult brain. Integr. Biol. (Camb.) 2009, 1:394-403.
103. Stachowiak M.K., Stachowiak E.K., Aletta J.M., Tzanakakis E.S. A common integrative nuclear signaling module for stem cell development. Stem Cells from Mechanisms to Technologies 2011, 87-132. World Scientific. E.S.T.M.K. Stachowiak (Ed.).
104. Stolerman I.P., Mirza N.R., Hahn B., Shoaib M. Nicotine in an animal model of attention. Eur. J. Pharmacol. 2000, 393:147-154.
105. Suemaru K., Yasuda K., Umeda K., Araki H., Shibata K., Choshi T., Hibino S., Gomita Y. Nicotine blocks apomorphine-induced disruption of prepulse inhibition of the acoustic startle in rats: possible involvement of central nicotinic alpha7 receptors. Br. J. Pharmacol. 2004, 142:843-850.
106. Sun J., Jia P., Fanous A.H., van den Oord E., Chen X., Riley B.P., Amdur R.L., Kendler K.S., Zhao Z. Schizophrenia gene networks and pathways and their applications for novel candidate gene selection. PLoS One 2010, 5:e11351.
107. Swerdlow N.R., Taaid N., Oostwegel J.L., Randolph E., Geyer M.A. Towards a cross-species pharmacology of sensorimotor gating: effects of amantadine, bromocriptine, pergolide and ropinirole on prepulse inhibition of acoustic startle in rats. Behav. Pharmacol. 1998, 9:389-396.
108. Swerdlow N.R., Weber M., Qu Y., Light G.A., Braff D.L. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl.) 2008, 199:331-388.
109. Terwisscha van Scheltinga A.F., Bakker S.C., Kahn R.S. Fibroblast growth factors in schizophrenia. Schizophr. Bull. 2010, 36:1157-1166.
110. Thompson J.L., Pogue-Geile M.F., Grace A.A. Developmental pathology, dopamine, and stress: a model for the age of onset of schizophrenia symptoms. Schizophr. Bull. 2004, 30:875-900.
111. Tidey J.W., Rohsenow D.J., Kaplan G.B., Swift R.M. Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls. Drug Alcohol Depend. 2005, 80:259-265.
112. Tietje K.R., Anderson D.J., Bitner R.S., Blomme E.A., Brackemeyer P.J., Briggs C.A., Browman K.E., Bury D., Curzon P., Drescher K.U., Frost J.M., Fryer R.M., Fox G.B., Gronlien J.H., Hakerud M., Gubbins E.J., Halm S., Harris R., Helfrich R.J., Kohlhaas K.L., Law D., Malysz J., Marsh K.C., Martin R.L., Meyer M.D., Molesky A.L., Nikkel A.L., Otte S., Pan L., Puttfarcken P.S., Radek R.J., Robb H.M., Spies E., Thorin-Hagene K., Waring J.F., Ween H., Xu H., Gopalakrishnan M., Bunnelle W.H. Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. CNS Neurosci. Ther. 2008, 14:65-82.
113. Toru M., Nishikawa T., Mataga N., Takashima M. Dopamine metabolism increases in post-mortem schizophrenic basal ganglia. J. Neural Transm. 1982, 54:181-191.
114. Trokovic R., Trokovic N., Hernesniemi S., Pirvola U., Vogt Weisenhorn D.M., Rossant J., McMahon A.P., Wurst W., Partanen J. FGFR1 is independently required in both developing mid- and hindbrain for sustained response to isthmic signals. EMBO J. 2003, 22:1811-1823.
115. Trokovic R., Jukkola T., Saarimaki J., Peltopuro P., Naserke T., Weisenhorn D.M., Trokovic N., Wurst W., Partanen J. Fgfr1-dependent boundary cells between developing mid- and hindbrain. Dev. Biol. 2005, 278:428-439.
116. Turner C.A., Akil H., Watson S.J., Evans S.J. The fibroblast growth factor system and mood disorders. Biol. Psychiatry 2006, 59:1128-1135.
117. Turner C.A., Calvo N., Frost D.O., Akil H., Watson S.J. The fibroblast growth factor system is downregulated following social defeat. Neurosci. Lett. 2008, 430:147-150.
118. Vagenakis G.A., Hyphantis T.N., Papageorgiou C., Protonatariou A., Sgourou A., Dimopoulos P.A., Mavreas V., Vagenakis A.G., Georgopoulos N.A. Kallmann's syndrome and schizophrenia. Int. J. Psychiatry Med. 2004, 34:379-390.
119. van der Kooy D., Hattori T. Dorsal raphe cells with collateral projections to the caudate-putamen and substantia nigra: a fluorescent retrograde double labeling study in the rat. Brain Res. 1980, 186:1-7.
120. Wallace T.L., Callahan P.M., Tehim A., Bertrand D., Tombaugh G., Wang S., Xie W., Rowe W.B., Ong V., Graham E., Terry A.V., Rodefer J.S., Herbert B., Murray M., Porter R., Santarelli L., Lowe D.A. RG3487, a novel nicotinic alpha7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J. Pharmacol. Exp. Ther. 2011, 336:242-253.
121. Williams E.J., Walsh F.S., Doherty P. The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. J. Cell Biol. 2003, 160:481-486.
122. Williams J.M., Gandhi K.K., Lu S.E., Kumar S., Shen J., Foulds J., Kipen H., Benowitz N.L. Higher nicotine levels in schizophrenia compared with controls after smoking a single cigarette. Nicotine Tob. Res. 2010, 12:855-859.
123. Winterer G. Why do patients with schizophrenia smoke?. Curr. Opin. Psychiatry 2010, 23:112-119.
124. Wong A.H., Van Tol H.H. Schizophrenia: from phenomenology to neurobiology. Neurosci. Biobehav. Rev. 2003, 27:269-306.
125. Wong J., Woon H.G., Weickert C.S. Full length TrkB potentiates estrogen receptor alpha mediated transcription suggesting convergence of susceptibility pathways in schizophrenia. Mol. Cell. Neurosci. 2011, 46:67-78.
126. Woznica A.A., Sacco K.A., George T.P. Prepulse inhibition deficits in schizophrenia are modified by smoking status. Schizophr. Res. 2009, 112:86-90.
127. Yi Yang R.C., Becker Chani, Terranova Christopher, Stachowiak Michal K., Wersinger Scott R. Impaired Performance on an Object Recognition Task Suggests a Working Memory Deficit in a Mouse Model of Schizophrenia 2010, Society for Neuroscience, San Diego, CA.
128. Zheng C., Shen Y., Xu Q. Association of intron 1 variants of the dopamine transporter gene with schizophrenia. Neurosci. Lett. 2012, 513:137-140.
129. Zhong K.X., Sweitzer D.E., Hamer R.M., Lieberman J.A. Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. J. Clin. Psychiatry 2006, 67:1093-1103.
130. Zigmond M.J., Acheson A.L., Stachowiak M.K., Stricker E.M. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch. Neurol. 1984, 41:856-861.